Can Viking Therapeutics Inc. (VKTX) Remain Competitive? – News Heater
Home  »  Trending   »  Can Viking Therapeutics Inc. (VKTX) Remain Competi...

Can Viking Therapeutics Inc. (VKTX) Remain Competitive?

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Viking Therapeutics Inc. (NASDAQ:VKTX) went up by 9.70% from its latest closing price compared to the recent 1-year high of $10.09. The company’s stock price has collected 6.64% of gains in the last five trading sessions. Press Release reported 19 hours ago that Viking Therapeutics to Participate in Upcoming Investor Conferences

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Is It Worth Investing in Viking Therapeutics Inc. (NASDAQ :VKTX) Right Now?

Plus, the 36-month beta value for VKTX is at 1.83. Opinions of the stock are interesting as 12 analysts out of 13 who provided ratings for Viking Therapeutics Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”


5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored



The average price from analysts is $18.92. VKTX currently public float of 70.20M and currently shorts hold a 14.46% ratio of that float. Today, the average trading volume of VKTX was 940.00K shares.

VKTX’s Market Performance

VKTX stocks went up by 6.64% for the week, with a monthly drop of -6.80% and a quarterly performance of -17.60%, while its annual performance rate touched -28.50%. The volatility ratio for the week stands at 3.72% while the volatility levels for the past 30 days are set at 4.40% for Viking Therapeutics Inc.. The simple moving average for the period of the last 20 days is 9.84% for VKTX stocks with a simple moving average of -3.02% for the last 200 days.

Analysts’ Opinion of VKTX

Many brokerage firms have already submitted their reports for VKTX stocks, with Raymond James repeating the rating for VKTX by listing it as a “Outperform.” The predicted price for VKTX in the upcoming period, according to Raymond James is $12 based on the research report published on May 25th of the current year 2021.

BMO Capital Markets, on the other hand, stated in their research note that they expect to see VKTX reach a price target of $14. The rating they have provided for VKTX stocks is “Outperform” according to the report published on June 05th, 2020.

Chardan Capital Markets gave a rating of “Buy” to VKTX, setting the target price at $15 in the report published on May 05th of the previous year.

VKTX Trading at 5.03% from the 50-Day Moving Average

After a stumble in the market that brought VKTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.90% of loss for the given period.

Volatility was left at 4.40%, however, over the last 30 days, the volatility rate increased by 3.72%, as shares surge +4.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.82% lower at present.

During the last 5 trading sessions, VKTX rose by +18.06%, which changed the moving average for the period of 200-days by -22.28% in comparison to the 20-day moving average, which settled at $5.63. In addition, Viking Therapeutics Inc. saw -0.18% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at VKTX starting from FOEHR MATTHEW W, who purchase 20,000 shares at the price of $5.69 back on Jun 10. After this action, FOEHR MATTHEW W now owns 66,250 shares of Viking Therapeutics Inc., valued at $113,800 using the latest closing price.

LIGAND PHARMACEUTICALS INC, the 10% Owner of Viking Therapeutics Inc., sale 94,488 shares at $8.11 during a trade that took place back on Aug 26, which means that LIGAND PHARMACEUTICALS INC is holding 5,819,383 shares at $766,109 based on the most recent closing price.

Stock Fundamentals for VKTX

The total capital return value is set at -16.33, while invested capital returns managed to touch -15.14. Equity return is now at value -17.60, with -16.80 for asset returns.

Based on Viking Therapeutics Inc. (VKTX), the company’s capital structure generated 0.15 points at debt to equity in total, while total debt to capital is 0.15. Total debt to assets is 0.14, with long-term debt to equity ratio resting at 0.01. Finally, the long-term debt to capital ratio is 0.01.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

The liquidity ratio also appears to be rather interesting for investors as it stands at 21.12.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

A Lesson to Learn: 2U Inc. (TWOU)

2U Inc. (NASDAQ:TWOU) went up by 3.89% from its latest closing price compared to the recent 1-year high of $59.74. The company’s stock price has

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.